Phase Ib Trial of MSP3 LSP in Children in Tanzania

Phase Ib Trial of MSP3 LSP in Children in Tanzania

Objectives

This study will evaluate the safety of candidate malaria vaccine MSP3 in children aged 12-24 months in Tanzania in a highland area with low malaria transmission.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

http://ClinicalTrials.gov/show/NCT00469651

Key facts

  • Dates
    Oct 2007 to Aug 2008
    Country
    • Tanzania, United Republic of

MESA tags

  • Methodology
    Product development & clinical research
    Theme(s)
    Immune correlates of protection